Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review

@article{Knight2009MycophenolateMD,
  title={Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review},
  author={S. Knight and N. Russell and L. Barcena and P. Morris},
  journal={Transplantation},
  year={2009},
  volume={87},
  pages={785-794}
}
  • S. Knight, N. Russell, +1 author P. Morris
  • Published 2009
  • Medicine
  • Transplantation
  • Background. Mycophenolate mofetil (MMF) has increasingly replaced azathioprine (AZA) as the antimetabolite of choice in immunosuppressive protocols. Initial trials comparing MMF with AZA in patients receiving cyclosporine A sandimmune showed a clinical benefit in reducing the incidence of acute rejections. It has been questioned whether this benefit remains significant when using newer formulations of cyclosporine A (neoral) and tacrolimus. Methods. Literature searches were performed using the… CONTINUE READING
    Comparison of azathioprine with mycophenolate mofetil in a living donor kidney transplant programme
    7

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 55 REFERENCES
    Efficacy of mycophenolate mofetil versus azathioprine after renal transplantation: a systematic review.
    15
    Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review.
    87